Page 1

HALF - YEAR REPORT 2021 January - June 2021 Preparing Oncoral for the next level SIGNIFICANT EVENTS IN Q2 2021 ■ EGM approval of the directed new share issue Issuance and repurchase of C - shares for share saving program SIGNIFICANT EVENTS AFTER THE PERIOD Covid - 19 effect extends recruitment period for SPARKLE study with up to 6 months into H1 2022 ( previously H2 2021 ) Abstract for Orviglance comparison study to gadolinium accepted as an oral paper presentation at the world's largest radiology conference RSNA FDA conditionally accepted Orviglance® as the brand name for Mangoral KEY RATIOS GROUP We are excited to move our second drug candidate Oncoral forward and expect to start Phase 2 later this year according to plan Q2 ( Apr - Jun ) 2021 RÖRELSERESULTAT ( MSEK ) -32.3 -0.99 2020 VINST PER AKTIE ( SEK ) -30.6 -28.6 319.0 -1.31 ASCELIA PHARMA -20.7 Advancing Orphan Oncology KASSAFLÖDE FRÅN DEN LÖPANDE VERKSAMHETEN ( MSEK ) 144.9 H1 ( Jan - Jun ) 2021 -64.7 -1.99 LIKVIDA MEDEL INKL . KORTFRISTIGA PLACERINGAR ( MSEK ) 319.0 -53.6 2020 -49.3 -2.02 -39.1 144.9